Zoetis (ZTS) has been experiencing a turbulent market response, owing to concerns over its arthritis drugs showing potential adverse impacts on pets. The global leader in animal health medicines has successfully outperformed expectations in
Q1 2024 earnings with significant growth in revenue and net income, which resulted in a brief stock upsurge. However, amidst highs and lows, the stock has seen a general downward trajectory. Notable mentions include Zoetis's participation in
Stifel's 2024 Jaws and Paws conference, its recognition as a top company for DE&I by Fair360, and its planned sale of a medicated feed additive portfolio to Phibro Animal Health. As Zoetis approaches
Q2 2024, it has consistently surpassed estimates. While the company holds promise from investment perspectives, investors are encouraged to remain vigilant towards lawsuit risks. Zoetis has been hit with a European probe over potential breaches of competition rules, which resulted in a drop in its stock prices. Despite the challenges, Zoetis continued to receive a consensus rating of 'buy' from brokerages.
Zoetis ZTS News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Thu, 16 May 2024 16:47:37 GMT -
Rating -3
- Innovation 5
- Information 7
- Rumor -2
